Current position:News > News > Insights
AstraZeneca Announces Data from First-in-Human Phase 1 Study of AZD0486, a Novel CD19xCD3 T-Cell Activator, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
吉满生物
2024-11-08

On 7 Nov, AstraZeneca announced that it will present clinical results for its next-generation T-cell splicer, AZD0486, in relapsed/refractory follicular lymphoma (R/R FL) at this year's American Society of Hematology (ASH) Annual Meeting.

image.png

AZD0486, a novel IgG4 fully human CD19xCD3 bispecific T-cell engager (TCE), is uniquely designed to bind CD3 with low affinity to reduce cytokine release upon T-cell activation, while preserving effective T-cell cytotoxicity against malignant B cells. AZD0486 was active and well tolerated in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), including those with R/R diffuse large B-cell lymphoma (DLBCL) (Gaballa, et al. Blood. 2023). Here, we present interim results from the ongoing phase 1, dose-escalation trial of AZD0486 in pts with R/R DLBCL (NCT04594642).  


9595de002183040bf4cd1b1920c6ea1b.png

Drug structure of AZD0486


Conclusion: AZD0486 is active in pts with heavily pretreated DLBCL and responses appear to be target dose–dependent at least up to 15 mg. At target doses evaluated, AZD0486 was well tolerated, with 2SUD mitigating CRS and ICANS events. Dose escalation is ongoing.


Learn more about our CD19/CD3 catalog.

Latest news
Insights
2025-12-24
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
Insights
2025-12-24
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
Insights
2025-12-17
Could GDF15 Become the Next Super Target After PD-1 and GLP-1?
A recent Nature Aging study reveals that senescent tumor-adjacent epithelial cells secrete GDF15, driving colorectal cancer progression via a metabolic–epigenetic feedback loop. This expands GDF15’s role beyond tumor cells to its influence on the surrounding microenvironment.

Emerging as a hub connecting tumor growth, immune evasion, and systemic metabolism, GDF15 is a promising target across oncology, cancer cachexia, obesity, and metabolic diseases. Monoclonal antibodies like Ponsegromab and Visugromab are showing encouraging results in early clinical trials.
Current position:News > News > Insights
classify
AstraZeneca Announces Data from First-in-Human Phase 1 Study of AZD0486, a Novel CD19xCD3 T-Cell Activator, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
吉满生物
2024-11-08

On 7 Nov, AstraZeneca announced that it will present clinical results for its next-generation T-cell splicer, AZD0486, in relapsed/refractory follicular lymphoma (R/R FL) at this year's American Society of Hematology (ASH) Annual Meeting.

image.png

AZD0486, a novel IgG4 fully human CD19xCD3 bispecific T-cell engager (TCE), is uniquely designed to bind CD3 with low affinity to reduce cytokine release upon T-cell activation, while preserving effective T-cell cytotoxicity against malignant B cells. AZD0486 was active and well tolerated in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), including those with R/R diffuse large B-cell lymphoma (DLBCL) (Gaballa, et al. Blood. 2023). Here, we present interim results from the ongoing phase 1, dose-escalation trial of AZD0486 in pts with R/R DLBCL (NCT04594642).  


9595de002183040bf4cd1b1920c6ea1b.png

Drug structure of AZD0486


Conclusion: AZD0486 is active in pts with heavily pretreated DLBCL and responses appear to be target dose–dependent at least up to 15 mg. At target doses evaluated, AZD0486 was well tolerated, with 2SUD mitigating CRS and ICANS events. Dose escalation is ongoing.


Learn more about our CD19/CD3 catalog.

Message consultation
reset
submit
Message
Message consultation
reset
submit